Prior Auth Required

13239 - TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / ServiceTRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023
Procedure / Service Description

for Medicare & Medicaid Services. Available at: https://www.cms.gov/newsroom/press-releases/statement- - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT04437511 9 Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The 7/2023 7/2024 TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023.13239 10 Ksiunla [prescribing information]. Eli Lilly and Company. Indianapolis, IN. 7/2024 7/2024 CAPITAL DISTRICT PHYSICIANS’ HEALTH PLAN, INC.

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.